Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2022-08-11 Report Publication Anno…
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2022
Report Publication Announcement Classification · 99% confidence The document text is extremely short (470 characters) and explicitly states 'Interim report for 1H 2022' but then directs the reader to 'Please read the full announcement in PDF' and provides an attachment link. This structure indicates that the document itself is an announcement about the release of a report, rather than the comprehensive report (which would be classified as IR). According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement pointing to a full report should be classified as a Report Publication Announcement (RPA). The content relates to an 'Interim report', which aligns with the scope of IR, but the format dictates RPA.
2022-08-11 English
Interim report for 1H 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for 1H 2022' and contains comprehensive financial data, including income statements, sales performance by business area and geography, and key financial metrics (EBIT, EBITDA, ROIC, FCF). It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-11 English
Transaction in Own Shares 2022
Transaction in Own Shares Classification · 100% confidence The document explicitly details transactions made under Novozymes' stock buyback program, providing accumulated figures, daily transaction volumes, average purchase prices, and detailed trade logs for the period of June 20th to June 24th, 2022. This content directly relates to the company acquiring its own shares, which aligns perfectly with the definition of 'Transaction in Own Shares' (POS). It is not a general regulatory filing (RNS), an earnings release (ER), or a comprehensive annual/interim report (10-K/IR).
2022-06-27 English
Transactions under Novozymes’ stock buyback program
Transaction in Own Shares Classification · 98% confidence The document is a short announcement (529 characters) regarding a stock buyback program. It explicitly states 'Please read the full announcement in the attached PDF' and provides a link to an attachment. According to the 'Menu vs Meal' rule, this is an announcement of a report/transaction rather than the transaction report itself, and it specifically relates to the company buying back its own shares.
2022-06-27 English
Transaction in Own Shares 2022
Transaction in Own Shares Classification · 100% confidence The document explicitly details transactions under Novozymes' stock buyback program, providing accumulated figures, daily transaction breakdowns (number of shares, average price, transaction value), and detailed trade logs for specific dates in June 2022. This content directly relates to the company repurchasing its own shares. This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS). It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K), but a specific disclosure about share repurchase activity.
2022-06-20 English
Transactions under Novozymes’ stock buyback program
Transaction in Own Shares Classification · 98% confidence The document is a short announcement (529 characters) regarding a stock buyback program. It explicitly states 'Please read the full announcement in the attached PDF' and provides a link to the attachment. According to the 'Menu vs Meal' rule, this is an announcement of a report/transaction rather than the transaction report itself, and it specifically relates to the company buying back its own shares.
2022-06-20 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.